Circio Holding ASA

Equities

TRVX

NO0013033795

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
2.7 ^NOK	+0.75%		-6.90%	-62.50%

Apr. 25	Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 17	Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	MT

Circio Holding ASA Reports Earnings Results for the Half Year Ended June 30, 2023

August 24, 2023 at 04:12 am EDT

Circio Holding ASA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was NOK 75.96 million compared to NOK 59.6 million a year ago. Basic loss per share from continuing operations was NOK 12 compared to NOK 9.6 a year ago.

Latest news about Circio Holding ASA

Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	Apr. 17	MT
Circio to Raise Up to NOK60 Million via Rights Issue	Apr. 17	MT
Circio Terminates Cancer Vaccine License Deal in China	Apr. 17	MT
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus	Apr. 17	CI
Transcript : Circio Holding ASA - Special Call	Apr. 17
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment	Apr. 17	CI
Circio Partner Exercises Option to License Cancer Vaccine in China	Mar. 19	MT
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China	Mar. 19	CI
Atlas Special Opportunities Converts Circio's Convertible Bonds to Shares	Feb. 05	MT
Circio Doses First Patient in Phase 2 Trial of Cancer Vaccine	Feb. 01	MT
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University	Feb. 01	CI
Circio Gets Approval for EUR6 Million Loans Waiver for Tumor Cell Technology Development	Jan. 18	MT
Circio Holding Asa Receives Waiver of Eur 6.2 Million in Loans from Business Finland	Jan. 18	CI
Atlas Special Opportunities Converts NOK1 Million of Circio Convertible Bonds	Jan. 10	MT
Circio Partner Files Investigational New Drug Application for Cancer Vaccine in China	Dec. 12	MT
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration	Dec. 12	CI
Circio to Begin Clinical Trial for Blood Cancer Vaccine After Successful Safety Review	Dec. 07	MT
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital	Dec. 07	CI
Transcript : Circio Holding ASA - Special Call	Nov. 29
Circio Joins Collaboration to Test the Combination of TG01 Vaccination with Daratumumab and Nivolumab in Immunotherapy-Resistant Patients with Mutant RAS Cancers	Nov. 16	CI
Georgetown University-led Collaboration to Test Circio's Drug Candidate Against RAS-mutated Cancers	Nov. 16	MT
Circio Holding ASA Announces Management Changes	23-10-18	CI
Transcript : Circio Holding ASA - Special Call	23-10-11
Circio, Neoregen Biotech Enter Research Partnership on Circular RNA Therapeutics	23-10-10	MT

Chart Circio Holding ASA

Duration

Period

More charts

Company Profile

Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circioâs second clinical program is an immunotherapy targeting KRAS driver mutations.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Circio Holding ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.7 NOK

Average target price

48 NOK

Spread / Average Target

+1,677.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CIRCIO HOLDING ASA	-62.50%	1.86M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs